202 related articles for article (PubMed ID: 20418240)
21. Evaluation of aprepitant for acute chemotherapy-induced nausea and vomiting in children and adolescents with acute lymphoblastic leukemia receiving high-dose methotrexate.
Felix-Ukwu F; Reichert K; Bernhardt MB; Schafer ES; Berger A
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 29031010
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic value of black seed oil in methotrexate hepatotoxicity in Egyptian children with acute lymphoblastic leukemia.
Hagag AA; AbdElaal AM; Elfaragy MS; Hassan SM; Elzamarany EA
Infect Disord Drug Targets; 2015; 15(1):64-71. PubMed ID: 25809628
[TBL] [Abstract][Full Text] [Related]
23. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Münster Group.
Dördelmann M; Schrappe M; Reiter A; Zimmermann M; Graf N; Schott G; Lampert F; Harbott J; Niemeyer C; Ritter J; Dörffel W; Nessler G; Kühl J; Riehm H
Leukemia; 1998 May; 12(5):645-51. PubMed ID: 9593260
[TBL] [Abstract][Full Text] [Related]
24. Association of -24CT, 1249GA, and 3972CT ABCC2 gene polymorphisms with methotrexate serum levels and toxic side effects in children with acute lymphoblastic leukemia.
Sharifi MJ; Bahoush G; Zaker F; Ansari S; Rafsanjani KA; Sharafi H
Pediatr Hematol Oncol; 2014 Mar; 31(2):169-77. PubMed ID: 24552501
[TBL] [Abstract][Full Text] [Related]
25. Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia--a logistic regression analysis.
Rask C; Albertioni F; Bentzen SM; Schroeder H; Peterson C
Acta Oncol; 1998; 37(3):277-84. PubMed ID: 9677100
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study.
Balis FM; Holcenberg JS; Poplack DG; Ge J; Sather HN; Murphy RF; Ames MM; Waskerwitz MJ; Tubergen DG; Zimm S; Gilchrist GS; Bleyer WA
Blood; 1998 Nov; 92(10):3569-77. PubMed ID: 9808549
[TBL] [Abstract][Full Text] [Related]
27. [Assessment of elimination and tolerance of high dose of methotrexate (3 g/m2) in children with standard-risk acute lymphoblastic leukemia].
Cwliklińska M; Balwierz W; Nowak J; Stanuch H
Przegl Lek; 2006; 63(1):15-20. PubMed ID: 16892893
[TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia.
Medellin-Garibay SE; Hernández-Villa N; Correa-González LC; Morales-Barragán MN; Valero-Rivera KP; Reséndiz-Galván JE; Ortiz-Zamudio JJ; Milán-Segovia RDC; Romano-Moreno S
Cancer Chemother Pharmacol; 2020 Jan; 85(1):21-31. PubMed ID: 31673826
[TBL] [Abstract][Full Text] [Related]
29. A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities.
Foster JH; Thompson PA; Bernhardt MB; Margolin JF; Hilsenbeck SG; Jo E; Marquez-Do DA; Scheurer ME; Schafer ES
Cancer Chemother Pharmacol; 2019 Feb; 83(2):349-360. PubMed ID: 30488179
[TBL] [Abstract][Full Text] [Related]
30. Population Pharmacokinetic Study and Individual Dose Adjustments of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia or Osteosarcoma.
Hui KH; Chu HM; Fong PS; Cheng WTF; Lam TN
J Clin Pharmacol; 2019 Apr; 59(4):566-577. PubMed ID: 30556906
[TBL] [Abstract][Full Text] [Related]
31. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.
Radtke S; Zolk O; Renner B; Paulides M; Zimmermann M; Möricke A; Stanulla M; Schrappe M; Langer T
Blood; 2013 Jun; 121(26):5145-53. PubMed ID: 23652803
[TBL] [Abstract][Full Text] [Related]
32. [High methotrexate doses in the treatment program for acute lymphoblastic leukemia and lymphosarcoma in children].
Makhonova LA; Maiakova SA; Kiselev AV; Gordina GA; Balakirev SA; Gavrilova IE; Moiseenko EI; Morozova OV
Vopr Onkol; 1990; 36(10):1196-200. PubMed ID: 2251813
[TBL] [Abstract][Full Text] [Related]
33. Impact of therapy in a cohort of unselected children with Down Syndrome-associated Acute Lymphoblastic Leukaemia.
Derouet A; Petit A; Baruchel A; Clavel J; Brethon B; Bertrand Y; Lutz P; Nacka F; Ducassou S
Br J Haematol; 2016 Sep; 174(6):983-5. PubMed ID: 26457881
[No Abstract] [Full Text] [Related]
34. [Acute leukemia in patients with Down syndrome].
Fernández-Plaza S; Sevilla J; Contra T; Martín N; Madero L
An Pediatr (Barc); 2004 Dec; 61(6):515-9. PubMed ID: 15574252
[TBL] [Abstract][Full Text] [Related]
35. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
36. Methotrexate sensitivity in Down's syndrome: a hypothesis.
Ueland PM; Refsum H; Christensen B
Cancer Chemother Pharmacol; 1990; 25(5):384-6. PubMed ID: 2137726
[No Abstract] [Full Text] [Related]
37. Wernicke's encephalopathy in a child with Down syndrome, undergoing treatment for acute lymphoblastic leukemia.
Yıldırım AT; Bilgili G; Akman B; Ovalı GY; Özgüven AA; Gülen H
Pediatr Int; 2016 Aug; 58(8):757-9. PubMed ID: 27324305
[No Abstract] [Full Text] [Related]
38. Outcome of acute lymphoblastic leukemia in children with down syndrome-Polish pediatric leukemia and lymphoma study group report.
Zawitkowska J; Odój T; Drabko K; Zaucha-Prażmo A; Rudnicka J; Romiszewski M; Matysiak M; Kwiecińska K; Ćwiklińska M; Balwierz W; Owoc-Lempach J; Derwich K; Wachowiak J; Niedźwiecki M; Adamkiewicz-Drożyńska E; Trelińska J; Młynarski W; Kołtan A; Wysocki M; Tomaszewska R; Szczepański T; Płonowski M; Krawczuk-Rybak M; Ociepa T; Urasiński T; Mizia-Malarz A; Sobol-Milejska G; Karolczyk G; Kowalczyk J
Pediatr Hematol Oncol; 2017 May; 34(4):199-205. PubMed ID: 29040012
[TBL] [Abstract][Full Text] [Related]
39. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma.
Shimasaki N; Mori T; Samejima H; Sato R; Shimada H; Yahagi N; Torii C; Yoshihara H; Tanigawara Y; Takahashi T; Kosaki K
J Pediatr Hematol Oncol; 2006 Feb; 28(2):64-8. PubMed ID: 16462575
[TBL] [Abstract][Full Text] [Related]
40. Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate.
Rask C; Albertioni F; Schrøder H; Peterson C
Pediatr Hematol Oncol; 1996; 13(4):359-67. PubMed ID: 8837142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
